Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cognition Therapeutics Inc

NASDAQ: CGTX · Life Sciences · 3 alerts · CIK 1455365

Share price
$0.6388Close, Nov 16
Market cap
$60.8M
Shares outstanding
95.1MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cognition Therapeutics Inc filings on SEC EDGAR ↗

6:16 AM ET 10-Q
Financial Results

Cognition Therapeutics Q3 2026 Results: Net Loss of $4.14M, Loss Narrows

Cognition Therapeutics reported a decrease in cash and cash equivalents to $30.8 million as of September 30, 2026, compared to $36.8 million at year-end 2025. The company's accumulated deficit grew to $211.3 million, reflecting ongoing clinical development costs for its lead product candidate, zervimesine (CT1812).

Key figure
Net loss $4.14M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.